Vangard

Vanguard Therapeutics is a private biotechnology company focused on developing novel small molecule therapies for orphan diseases, with a primary emphasis on sickle cell disease (SCD). The company's lead program is centered on a next-generation hemoglobin oxygen-affinity modulator designed to prevent the polymerization of sickle hemoglobin, thereby reducing the frequency of vaso-occlusive crises and chronic organ damage. By targeting the underlying pathophysiology of SCD, Vanguard aims to provide more effective and safer treatment options for patients suffering from this debilitating genetic disorder. The company is currently advancing its lead candidate through pre-clinical development toward IND-enabling studies.